Mathieu Rouanne

8.1k citations

69 papers · 4.6k indexed · 6 hit papers · h-index 24

Impact in

Urology top 0.2%
- Urological Disorders and Treatments
Surgery top 0.5%
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies

Papers in ⓘ

Urology 12
- Urological Disorders and Treatments 11
Surgery 42
- Bladder and Urothelial Cancer Treatments 38
- Urinary and Genital Oncology Studies 27

Co-authors: Y. Neuzillet (32 shared papers)Éva Compérat (10 shared papers)Erik Veskimäe (8 shared papers)Georgios Gakis (8 shared papers)Antoine G. van der Heijden (7 shared papers)María J. Ribal (6 shared papers)Nigel C. Cowan (7 shared papers)J. Alfred Witjes (5 shared papers)
Journals: European Journal of Cancer (7 papers)European Urology (4 papers)European Urology Oncology (3 papers)Urologic Oncology Seminars and Original Investigations (3 papers)European Radiology (2 papers)
Partner nations: France United States Netherlands

In The Last Decade

Mathieu Rouanne

67 papers receiving 4.6k citations

Hit Papers

6 papers align trajectories log scale

Probiotic neoantigen delivery vectors for precision cancer immunotherapy 2024 · 70 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2024 Nature
2024 Immunity
2023 Science
2021 European Urology
2020 European Urology
2016 European Urology

Peers

Countries citing papers authored by Mathieu Rouanne

Since Specialization

Citations

This map shows the geographic impact of Mathieu Rouanne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathieu Rouanne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathieu Rouanne more than expected).

Fields of papers citing papers by Mathieu Rouanne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathieu Rouanne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathieu Rouanne. The network helps show where Mathieu Rouanne may publish in the future.

Co-authors

The 25 scholars most cited alongside Mathieu Rouanne, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mathieu Rouanne Line = papers co-authored together Mathieu Rouanne links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 69 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines European Urology ·J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, Éva Compérat, Nigel C. Cowan, Georgios Gakis, Virginia Hernández, Estefanía Linares, Anja Lorch, Y. Neuzillet, Mathieu Rouanne, George N. Thalmann, Erik Veskimäe, María J. Ribal, Antoine G. van der Heijden Hit paper breakdown →	2020	1278
2	Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer European Urology ·J. Alfred Witjes, Thierry Lebrét, Éva Compérat, Nigel C. Cowan, Maria De Santis, H.M. Bruins, Virginia Hernández, Estefanía Linares, James Dunn, Mathieu Rouanne, Y. Neuzillet, Erik Veskimäe, Antoine G. van der Heijden, Georgios Gakis, María J. Ribal Hit paper breakdown →	2016	1090
3	Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2‐weighted, dynamic contrast‐enhanced and diffusion‐weighted imaging British Journal of Urology ·Nicolas Barry Delongchamps, Mathieu Rouanne, T Flam, Frédéric Beuvon, Mathieu Liberatore, Marc Zerbib, F. Cornud	2010	251
4	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma European Urology ·Richard Cathomas, Anja Lorch, Harman Max Bruins, Éva Compérat, Nigel C. Cowan, Jason A. Efstathiou, Rainer Fietkau, Georgios Gakis, Virginia Hernández, Estefania Linares Espinós, Y. Neuzillet, María J. Ribal, Mathieu Rouanne, George N. Thalmann, Antoine G. van der Heijden, Erik Veskimäe, J. Alfred Witjes, Matthew I. Milowsky Hit paper breakdown →	2021	212
5	Targeting the DNA damage response in immuno-oncology: developments and opportunities Nature reviews. Cancer ·Roman M. Chabanon, Mathieu Rouanne, Christopher J. Lord, Jean‐Charles Soria, Philippe Pasero, Sophie Postel‐Vinay	2021	192
6	Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors European Urology ·Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun‐Ju Huang, Jean Paul Thiery	2018	192
7	Probiotic-guided CAR-T cells for solid tumor targeting Science ·Rosa L. Vincent, Candice R. Gurbatri, Fangda Li, Ana Vardoshvili, Courtney Coker, Jongwon Im, Edward R. Ballister, Mathieu Rouanne, Thomas Savage, Kenia de los Santos-Alexis, Andrew Redenti, Leonie Brockmann, Meghna Komaranchath, Nicholas Arpaia, Tal Danino Hit paper breakdown →	2023	146
8	Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Éva Compérat, S. Larré, Morgan Rouprêt, Y. Neuzillet, G. Pignot, H. Quintens, Nadine Houédé, Catherine Roy, Xavier Durand, Justine Varinot, Dimitri Vordos, Mathieu Rouanne, Mohammed Adnan Bakhri, P. Leon Bertrand, Stephane Calin Jeglinschi, Olivier Cussenot, M. Soulié, Christian Pfister	2015	132
9	Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways World Journal of Urology ·Mathieu Rouanne, M. Roumiguié, Nadine Houédé, A. Masson-Lecomte, Pierre Colin, G. Pignot, S. Larré, Évanguelos Xylinas, Morgan Rouprêt, Y. Neuzillet	2018	73
10	Probiotic neoantigen delivery vectors for precision cancer immunotherapy Nature ·Andrew Redenti, Jongwon Im, Benjamin Redenti, Fangda Li, Mathieu Rouanne, Zeren Sheng, William Sun, Candice R. Gurbatri, Shunyu Huang, Meghna Komaranchath, YoungUk Jang, Jaeseung Hahn, Edward R. Ballister, Rosa L. Vincent, Ana Vardoshivilli, Tal Danino, Nicholas Arpaia Hit paper breakdown →	2024	70
11	Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder European Urology Oncology ·Mathieu Rouanne, Dean F. Bajorin, Raquibul Hannan, Matthew D. Galsky, Stephen B. Williams, Andrea Necchi, Padmanee Sharma, Thomas Powles	2020	57
12	The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel European Urology Oncology ·Harman Max Bruins, Erik Veskimäe, Virginia Hernández, Y. Neuzillet, Richard Cathomas, Éva Compérat, Nigel C. Cowan, Georgios Gakis, Estefanía Linares, Anja Lorch, María J. Ribal, Mathieu Rouanne, George N. Thalmann, Yuhong Yuan, Antoine G. van der Heijden, J. Alfred Witjes	2019	57
13	Systematic review of the oncological and functional outcomes of pelvic organ‐preserving radical cystectomy ( RC ) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer British Journal of Urology ·Erik Veskimäe, Y. Neuzillet, Mathieu Rouanne, Steven MacLennan, Thomas Lam, Yuhong Yuan, Éva Compérat, Nigel C. Cowan, Georgios Gakis, Antoine G. van der Heijden, María J. Ribal, J. Alfred Witjes, Thierry Lebrét	2017	55
14	Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non–small cell lung cancer treated with immunotherapy European Journal of Cancer ·Ithar Gataa, Laura Mezquita, Caroline Rossoni, Édouard Auclin, Myriam Kossaï, Frank Aboubakar Nana, Sylvestre Le Moulec, Julie Massé, M. Masson, Nina Radosevic‐Robin, Pierre Alemany, Mathieu Rouanne, Virginia Bluthgen, Lizza Hendriks, Caroline Caramella, Anas Gazzah, David Planchard, Jean‐Pierre Pignon, Benjamin Besse, Julien Adam	2021	53
15	Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis Immunity ·Thomas Savage, Katherine T. Fortson, Kenia de los Santos-Alexis, Angelica Oliveras-Alsina, Mathieu Rouanne, Sarah S. Rae, Jennifer R. Gamarra, Hani Shayya, Adam Kornberg, Renzo Cavero, Fangda Li, Arnold Han, Rebecca A. Haeusler, Julien Adam, Robert F. Schwabe, Nicholas Arpaia Hit paper breakdown →	2024	53
16	Endorectal 3D T2-weighted 1mm-slice thickness MRI for prostate cancer staging at 1.5Tesla: Should we reconsider the indirects signs of extracapsular extension according to the D’Amico tumor risk criteria? European Journal of Radiology ·F. Cornud, Mathieu Rouanne, Frédéric Beuvon, D. Eiss, T Flam, Mauro Liberatore, Marc Zerbib, Nicolas Barry Delongchamps	2011	50
17	c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression Nature Communications ·Wen Jing Sim, Prasanna Vasudevan Iyengar, Dilraj Lama, Sarah Kit Leng Lui, Hsien Chun Ng, Lior Haviv-Shapira, Eytan Domany, Dennis Kappei, Tuan Zea Tan, Azad Saei, Patrick Jaynes, Chandra Verma, Alan Prem Kumar, Mathieu Rouanne, Hong Koo Ha, C. Radulescu, Peter ten Dijke, Pieter J.A. Eichhorn, Jean Paul Thiery	2019	48
18	Rationale for LDH-targeted cancer immunotherapy European Journal of Cancer ·Tina B.S. Miholjcic, Heloise M. Halse, Mélodie Bonvalet, Amélie Bigorgne, Mathieu Rouanne, Laurent Dercle, Vishnu Shankar, Aurélien Marabelle	2022	42
19	Integrated analysis of 18F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer European Radiology ·Antoine Girard, Mathieu Rouanne, Sarah Taconet, C. Radulescu, Y. Neuzillet, Astrid Girma, Aurélie Bèaufrere, Thierry Lebrét, Elise Le Stanc, Jean-François Grellier	2019	40
20	Novel therapeutic targets in advanced urothelial carcinoma Critical Reviews in Oncology/Hematology ·Mathieu Rouanne, Yohann Loriot, Thierry Lebrét, Jean‐Charles Soria	2015	37

About Mathieu Rouanne

Mathieu Rouanne is a scholar working on Urology, Surgery, Oncology, Pulmonary and Respiratory Medicine and Rheumatology, having authored 69 papers that have together received 4.6k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (38 papers), Urinary and Genital Oncology Studies (27 papers), Cancer Immunotherapy and Biomarkers (18 papers), Prostate Cancer Diagnosis and Treatment (13 papers), Urological Disorders and Treatments (11 papers), Prostate Cancer Treatment and Research (9 papers), Immunotherapy and Immune Responses (6 papers) and Hormonal and reproductive studies (5 papers). The work is most often cited by research in Urology (955 citations), Surgery (3.1k citations), Oncology (1.2k citations), Pulmonary and Respiratory Medicine (1.2k citations) and Cancer Research (487 citations). Mathieu Rouanne has collaborated with scholars based in France, United States and Netherlands. Frequent co-authors include Y. Neuzillet, Éva Compérat, Erik Veskimäe, Georgios Gakis, Antoine G. van der Heijden, María J. Ribal, Nigel C. Cowan, J. Alfred Witjes, Virginia Hernández and Estefanía Linares. Their work appears in journals such as European Journal of Cancer, European Urology, European Urology Oncology, Urologic Oncology Seminars and Original Investigations and European Radiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact